Page 36 - Recognizing axial spondyloarthritis - Janneke de Winter

CHAPTER TWO
the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008;35:869–876.
36. Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov VI, Myasoutova L, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis 2014;73:101–7.
37. Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014;73:48–55.
38. Landewé R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 2014;73:39–47.
39. Berg R Van Den, Gaalen F Van, Helm-Van Mil A Van Der, Huizinga T, Heijde D Van Der. Performance of classification criteria for peripheral spondyloarthritis and psoriatic arthritis in the Leiden early arthritis cohort. Ann Rheum Dis 2012;71:1366–1369.
40. Cheung PP, Tymms KE, Wilson BJ, Shadbolt B, Brook AS, Dorai Raj
AK, et al. Infliximab in severe active ankylosing spondylitis with spinal ankylosis. Intern Med J 2008;38:396– 401.
41. Tomero E, Mulero J, Miguel E de, Fernández-Espartero C, Gobbo M, Descalzo M a, et al. Performance of the Assessment of Spondyloarthritis International Society criteria for the classification of spondyloarthritis in early spondyloarthritis clinics participating in the ESPERANZA programme. Rheumatology (Oxford) 2014;53:353–60.
42. Haglund E, Bremander AB, Petersson IF, Strömbeck B, Bergman S, Jacobsson LTH, et al. Prevalence of spondyloarthritis and its subtypes in southern Sweden. Ann Rheum Dis 2011;70:943–948.
43. Gladman DD. Toward treating to target in psoriatic arthritis. J Rheumatol 2015;93:14–16.
44. Mens LJJ Van, Sande MGH Van De, Kuijk AWR Van, Baeten D, Coates LC. Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a reallife cohort. Ann Rheum Dis 2018;77:251– 257.
45. Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 2010;62:965– 969.
46. Turina MC, Ramiro S, Baeten DL, Mease P, Paramarta JE, Song IH, et al. A psychometric analysis of outcome measures in peripheral spondyloarthritis. Ann Rheum Dis 2016;75:1302–1307.
34